Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

83.55 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Tempus AI Up Nearly 185% Since Nancy Pelosi's Reported Purchase In January 2025 ↗

October 10, 2025

Track Nancy Pelosi's 2025 stock trades. Disclosures reveal a Tempus AI (TEM) options buy nets huge gains along with a Broadcom move.

Via Benzinga

Topics Artificial Intelligence

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

October 09, 2025

From Tempus AI, Inc.

Via Business Wire

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall ↗

October 09, 2025

Tempus AI (TEM) stock has soared past $100, giving a 60% boost to billionaire Cliff Asness' TEM position in the AI-diagnostic stock.

Via Benzinga

Topics Artificial Intelligence

Tempus AI Executive Ryan Fukushima Sells $460,000 Worth Of Stock ↗

October 08, 2025

Tempus AI stock nudged higher after hours following insider sales by COO Ryan Fukushima's spouse under a pre-arranged trading plan.

Via Benzinga

Topics Artificial Intelligence

These 5 Beaten-Down Tech Stocks Could Catch Fire Next ↗

October 08, 2025

Highly shorted stocks with positive growth outlooks and improving market support are set up for short squeezes: this is a look at five.

Via MarketBeat

Topics Artificial Intelligence

Nancy Pelosi's Tempus Play Might Be Smartest Trade In Washington — Stock Surges 200% ↗

October 08, 2025

An AI stock disclosed as a new 2025 purchase by Nancy Pelosi is up over 200% since she took the position in January.

Via Benzinga

Topics Artificial Intelligence

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 06, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 03, 2025

Via Benzinga

Why Tempus AI Stock Was Motoring Higher This Week ↗

October 03, 2025

A recent acquisition seems to be paying off already for the tech-forward healthcare data specialist.

Via The Motley Fool

Topics Artificial Intelligence

AI Revolutionizes Professional Services: A New Era for Doctors, Lawyers, and Consultants

October 01, 2025

As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This...

Via MarketMinute

Topics Artificial Intelligence

Tempus AI (TEM) Stock Is Rising Wednesday: What's Going On? ↗

October 01, 2025

Shares of Tempus AI Inc (NASDAQ: TEM) are trading higher Wednesday, potentially building on momentum from last week given the lack of company-specific news. Here's what investors need to know.

Via Benzinga

Topics Artificial Intelligence

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

October 01, 2025

From Ambry Genetics

Via Business Wire

Affirm Holdings, Oklo, Tempus AI Are Among Top 10 Large Cap Losers Last Week (Sep. 22- Sep. 26): Are The Others In Your Portfolio? ↗

September 28, 2025

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Via Benzinga

Topics Artificial Intelligence

3 Healthcare Stocks Using AI to Drive Growth ↗

September 27, 2025

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

Via MarketBeat

Topics Artificial Intelligence

What Are 2 Great Tech Stocks to Buy Right Now? ↗

September 27, 2025

These two tech stocks could deliver big returns for investors willing to hold for the long term.

Via The Motley Fool

Topics Artificial Intelligence Stocks

7 Analysts Have This To Say About Tempus AI ↗

September 26, 2025

Tempus AI (NASDAQ: TEM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings,...

Via Benzinga

Topics Artificial Intelligence

Why Tempus AI Stock Is Plunging This Week ↗

September 25, 2025

When a well-known growth investor decides to trim her position in a stock, investors sit up and take note.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Cathie Wood Makes Trading Blitz: Buys Alibaba Stock Woth $11 Million, Dumps AMD And This AI Stock ↗

September 24, 2025

On Wednesday Sept. 24, 2025, Cathie Wood-led Ark Invest purchased nearly $11 million worth of Alibaba stock while selling shares of AMD and Tempus AI.

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here's What Ark Bought Instead ↗

September 23, 2025

Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.

Via Benzinga

Topics Artificial Intelligence

IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance ↗

September 22, 2025

The company is focusing on RNA sequencing as a means of assisting with drug development.

Via Investor's Business Daily

Topics Artificial Intelligence Intellectual Property

Tempus AI (TEM) Stock Is Rising Monday: What's Going On? ↗

September 22, 2025

Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.

Via Benzinga

Topics Artificial Intelligence

3 Big Short Interest Names with Bullish Setups ↗

September 22, 2025

HIMS, DLO, and TEM combine high short interest with bullish chart setups, creating strong breakout potential as market momentum stays hot.

Via MarketBeat

Topics Artificial Intelligence

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

September 22, 2025

From Tempus AI, Inc.

Via Business Wire

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% ↗

September 18, 2025

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

Via Benzinga

Topics Artificial Intelligence

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI ↗

September 16, 2025

On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. (NASDAQ:AMD) and Bullish Inc. (NYSE:BLSH), while selling shares o

Via Benzinga

What's Going On With Tempus AI Stock Monday? ↗

September 15, 2025

Tempus AI stock is trading marginally lower on Monday. Recent bullish sentiment follows last Thursday's announcement that Tempus AI received 510(k) clearance from the FDA.

Via Benzinga

Topics Artificial Intelligence

Cathie Wood's Ark Pivots: Sells Tempus AI After FDA Win, Loads Up On Amazon, Figma And This Trendy Crypto Stock ↗

September 11, 2025

Cathie Wood-led Ark Invest sold shares of Tempus AI, bought Bullish, Amazon, and Figma. The moves align with recent achievements and advancements of the companies.

Via Benzinga

Topics Artificial Intelligence

Why Tempus AI Stock Soared Nearly 14% Higher Today ↗

September 11, 2025

The AI heathcare tech specialist is about to put another product on the market.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.